NICM x Longevity Life Sciences: Award-Winning Early Research on CellVive NMN™ and Respiratory Health

Longevity Life Sciences is proud to share that our collaborative COPD model study, conducted with the NICM Health Research Institute (Western Sydney University) and led by Associate Professor Kamal (Kam) Dua, has been awarded 2nd Place for Best Poster at the 2025 International TransMedTech Conference.

This early-stage investigation explores the potential effects of CellVive NMN™ on inflammatory and respiratory pathways within a validated COPD model. The findings contribute to a growing body of research examining the role of NAD⁺ restoration in supporting cellular resilience and tissue health.

About the Research

Under the leadership of A/Prof Kam Dua — whose work spans pharmaceutics, inflammation biology, respiratory disease, and translational therapeutics — the study evaluated:

  • Inflammatory signalling pathways relevant to COPD and chronic respiratory stress
  • Markers associated with oxidative stress and cellular damage
  • Early indicators of NMN’s potential to modulate respiratory and immune responses

While results are preliminary and not yet indicative of clinical outcomes, the poster recognition highlights the scientific merit and future potential of this research direction.

A Growing Program of Translational Longevity Research

This COPD model project is part of LLS’s expanding research portfolio spanning respiratory, metabolic, and cognitive health, undertaken in collaboration with leading Australian and international institutions.

These studies contribute to:

  • A deeper understanding of NAD⁺ biology and NMN’s potential therapeutic applications
  • Foundations for future human trials
  • Evidence frameworks that support responsible progression into regulated therapeutic pathways

Looking Ahead

We congratulate our academic and industry collaborators, with special acknowledgement to A/Prof Kam Dua and the NICM research team for their ongoing leadership and scientific excellence.

As the work advances toward peer review and further investigation, Longevity Life Sciences remains committed to supporting rigorous, high-quality research that brings clarity, credibility, and clinical relevance to the field of cellular health.

longevity News

More From Longevity Life Sciences

Australia Becomes the First in the World to Approve NMN for Therapeutic Use

LLS at Wellspring: Reflections on NAD⁺, NMN & the Future of Cellular Health and Longevity with Professor David Sinclair